Microcap Ledger Processa Pharmaceuticals, Inc. $PCSA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Vero Beach, FL
- Fiscal year end
- December 31
- Shares outstanding
- 2,793,386 [10-Q 2026-08-14]
What the company doesAI summary of filing
Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer (NGC) therapies that modify how the body metabolizes or distributes existing, well-understood cancer drugs to improve efficacy and reduce toxicity. The company's lead program, NGC-Cap (PCS6422), combines a lower dose of capecitabine with an investigational compound and is currently in a Phase 2 trial in advanced or metastatic breast cancer. A second oncology candidate, NGC-Iri (PCS11T), is in preclinical development. The company is also evaluating non-oncology assets (PCS12852 for gastroparesis and PCS499 for glomerular disease) for out-licensing or partnership. Processa generates no revenue and funds development through equity and debt financing. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$6.64M | −$5.59M | $196.3K | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$13.56M | −$11.39M | $5.54M | [PRE 14A 2026-10-09] |
| FY ended Dec 2024 | — | −$11.85M | −$11.25M | $1.19M | [PRE 14A 2026-10-09] |
- Quarterly cash burn
- −$2.79M
- Cash runway Estimate
- ~0.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-12 | 5,269,240 | [10-K 2025-03-20] |
| 2025-05-08 | 11,884,356 | [10-Q 2025-05-08] |
| 2025-08-05 | 50,349,149 | [10-Q 2025-08-07] |
| 2025-11-03 | 56,644,223 | [10-Q 2025-11-06] |
| 2026-03-13 | 2,660,039 | [10-K 2026-03-18] |
| 2026-04-29 | 2,738,998 | [10-K/A 2026-04-30] |
| 2026-05-01 | 2,750,173 | [10-Q 2026-05-07] |
| 2026-08-07 | 2,793,386 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-10-09; no effectiveness notice found in EDGAR [S-3 2026-10-09]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-08-08. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-08-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-08] |
| 2025-02-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-10] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-08 | Ng George K | exercise | 1,600 | — | [4 2026-08-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | PRE 14A | Proxy statement |
| 2026-10-09 | PRE 14A | Proxy statement |
| 2026-10-09 | S-3 | Registration statement |
| 2026-10-05 | 8-K | Other events |
| 2026-08-18 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Director or officer change; Shareholder vote results |
| 2026-07-29 | 8-K | Material agreement entered; Material agreement terminated; Acquisition or disposition completed |
| 2026-06-18 | DEF 14A | Proxy statement |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-04-30 | 10-K/A | Amended report |
Alerts for $PCSA
Email me when Processa Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.